Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ALPHA trial: ALLO-501 in relapsed/refractory non-Hodgkin lymphoma

Sattva Neelapu • 29 May 2020
ASCO 2020
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Non-Hodgkin Lymphoma ALLO-501
ALPHA

Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, describes the Phase I ALPHA study (NCT03939026), evaluating the safety and efficacy of ALLO-501, an anti-CD19 allogeneic CAR T-cell in adults with relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL; FL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sattva Neelapu

Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL 4:50
Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
Sattva Neelapu • 12 Dec 2024
Next steps with ADI-001 0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma 2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies 3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
Durability of responses in patients with DLBCL treated with liso-cel: real-world insights 0:48
Durability of responses in patients with DLBCL treated with liso-cel: real-world insights
Krish Patel • 4 Sep 2025
The content of VJHemOnc is intended for healthcare professionals